Published in Anal Biochem on August 22, 2008
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
Fluorescence polarization assays in small molecule screening. Expert Opin Drug Discov (2011) 1.33
Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol (2012) 1.16
Structural basis for the inhibition of Polo-like kinase 1. Nat Struct Mol Biol (2013) 1.14
Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. Chembiochem (2012) 1.02
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci (2015) 0.87
Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development. Protein Cell (2012) 0.83
The application of modular protein domains in proteomics. FEBS Lett (2012) 0.82
Biophysical screening for the discovery of small-molecule ligands. Methods Mol Biol (2013) 0.76
Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. Sci Rep (2016) 0.75
Phosphatase-stable Phosphoamino Acid Mimetics that Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1. ChemMedChem (2016) 0.75
Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget (2016) 0.75
Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. Bioorg Med Chem (2017) 0.75
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38
Polo-like kinases and oncogenesis. Oncogene (2005) 2.86
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol (2008) 2.37
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 2.25
Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle (2010) 2.18
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle (2009) 1.75
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene (2004) 1.55
Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem (2004) 1.52
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol (2011) 1.49
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene (2002) 1.48
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48
Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol (2006) 1.35
Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem (2008) 1.34
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol (2002) 1.32
A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. Anal Biochem (2004) 1.32
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia (2005) 1.31
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst (2004) 1.29
T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity (2010) 1.29
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials (2006) 1.20
Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol (2012) 1.16
Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1. Mol Cell Biol (2010) 1.13
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun (2011) 1.12
Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle (2006) 1.10
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res (2006) 1.10
Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res (2006) 1.09
FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation. Blood (2012) 1.08
Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target (2004) 1.08
A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem (2009) 1.04
Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem (2005) 1.03
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 1.03
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer (2008) 1.03
Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. Chembiochem (2012) 1.02
Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem (2007) 1.01
The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer (2005) 1.00
FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle (2007) 1.00
Translocation biosensors to study signal-specific nucleo-cytoplasmic transport, protease activity and protein-protein interactions. Traffic (2005) 0.96
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol (2007) 0.95
SKAP1 protein PH domain determines RapL membrane localization and Rap1 protein complex formation for T cell receptor (TCR) activation of LFA-1. J Biol Chem (2011) 0.95
Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1. Oncogene (2005) 0.95
Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res (2002) 0.95
Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol (2010) 0.95
A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization. Anal Biochem (2008) 0.94
Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal Biochem (2009) 0.93
Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res (2006) 0.93
The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res (2007) 0.91
Silencing of mammalian genes by tetracycline-inducible shRNA expression. Nat Protoc (2007) 0.91
Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay. Proc Natl Acad Sci U S A (2009) 0.90
Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J Control Release (2004) 0.90
p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors. Cell Cycle (2012) 0.89
STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR. Anticancer Res (2005) 0.88
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. Bioorg Med Chem Lett (2009) 0.87
Demands on caring relatives of head and neck cancer patients. Laryngoscope (2007) 0.86
Adaptor SKAP-55 binds p21 activating exchange factor RasGRP1 and negatively regulates the p21-ERK pathway in T-cells. PLoS One (2008) 0.85
Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS. Pathol Res Pract (2005) 0.83
The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. Mol Cancer Ther (2010) 0.81
A scaffold-tree-merging strategy for prospective bioactivity annotation of gamma-pyrones. Angew Chem Int Ed Engl (2010) 0.81
Plk1: unexpected roles in DNA replication. Cell Res (2013) 0.81
Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN). Anticancer Res (2005) 0.81
Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression. J Drug Target (2009) 0.80
Polo-like kinases in AML. Expert Opin Investig Drugs (2012) 0.80
Selective targeting of disease-relevant protein binding domains by O-phosphorylated natural product derivatives. ACS Chem Biol (2011) 0.79
Reduction of cisplatin dosage by ZD 1839. Anticancer Res (2005) 0.79
RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy. Curr Pharm Des (2005) 0.79
Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a. Angew Chem Int Ed Engl (2015) 0.79
v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene (2004) 0.77
PYRROC: the first functionalized cycloalkyne that facilitates isomer-free generation of organic molecules by SPAAC. Org Biomol Chem (2015) 0.77
A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1. Methods Mol Biol (2012) 0.76
Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function. Int J Biol Markers (2015) 0.76
Synthesis and biochemical evaluation of highly enantiomerically pure (R,R)- and (S,S)-alexidine. Bioorg Med Chem (2013) 0.75
Oral disinfectants inhibit protein-protein interactions mediated by the anti-apoptotic protein Bcl-xL and induce apoptosis in human oral tumor cells. Angew Chem Int Ed Engl (2013) 0.75
The natural product betulinic acid inhibits C/EBP family transcription factors. Chembiochem (2011) 0.75
Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1. Bioorg Med Chem Lett (2011) 0.75
Binding of phosphorylated peptides and inhibition of their interaction with disease-relevant human proteins by synthetic metal-chelate receptors. J Mol Recognit (2010) 0.75